Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model
Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model
复制标题
DOI：
10.1111/j.1600-0765.2011.01428.x
复制
发表时间：
2012-04-01
影响因子：
3.5
通讯作者：
Wikesjoe, U. M. E.
中科院分区：
文献类型：
--
作者：
Bateman, J. P.;Safadi, F. F.;Wikesjoe, U. M. E.
背景和目的：骨激活素是一种新型糖蛋白，在成骨细胞分化和功能调节中发挥重要作用。本研究的目的是评估骨激活素的潜力，以支持骨再生，使用一个既定的defect model.Material和方法：临界尺寸，8毫米直径的通过和通过颅骨截骨缺损在60名成年雄性SD大鼠。试验动物接受0.1 mL溶于磷酸盐缓冲盐水（50 μ g/mL）的骨激活素，浸泡加载到可吸收胶原海绵上。对照组接受0.1 mL磷酸盐缓冲盐水浸泡加载到可吸收胶原海绵上或不进行进一步干预（假手术）。治疗后2周和4周处死动物，并进行组织计量学分析。（平均值+/-标准差：40.9 +/- 26.9%）与假手术相比，显示出边界显著更大的骨填充（22.9 +/- 15.8%; p = 0.10）和骨激活素（20.2 +/- 11.8%; p = 0.07）治疗。相比之下，骨激活素（84.7 +/- 15.8%）在4周时显示出显著高于假手术（28.4 +/- 9.6%; p < 0.001）和可吸收胶原海绵（41.8 +/- 22.1%; p < 0.001）的骨填充。没有动物接受假手术或可吸收的胶原蛋白海绵表现出完整的骨填充在4周，而70%的动物接受骨激活素显示完整的骨fill.Conclusion：骨激活素表现出显着的潜力，以支持骨再生/形成。使用有区别的大型动物模型的研究是必要的，以探索牙周和颅面适应症的临床应用。
Background and Objective: Osteoactivin is a novel glycoprotein shown to exhibit an important role in regulating osteoblast differentiation and function. The aim of the present study was to evaluate the potential of osteoactivin to support bone regeneration using an established defect model.Material and Methods: Critical-size, 8-mm-diameter through-and-through calvarial osteotomy defects were created in 60 adult male Sprague-Dawley rats. Test animals received 0.1 mL of osteoactivin in phosphate-buffered saline (50 mu g/mL) soak-loaded onto an absorbable collagen sponge. Controls received 0.1 mL of phosphate-buffered saline soak-loaded onto the absorbable collagen sponge or no further intervention (sham-surgery). The animals were euthanized 2 and 4 wk after treatment and histometric analyses were performed.Results: The absorbable collagen sponge control (mean +/- standard deviation: 40.9 +/- 26.9%) showed borderline significant greater bone fill compared with sham-surgery (22.9 +/- 15.8%; p = 0.10) and osteoactivin (20.2 +/- 11.8%; p = 0.07) treatments at 2 wk. In contrast, osteoactivin (84.7 +/- 15.8%) showed significantly greater bone fill than sham-surgery (28.4 +/- 9.6%; p < 0.001) and absorbable collagen sponge (41.8 +/- 22.1%; p < 0.001) at 4 wk. No animals receiving sham-surgery or absorbable collagen sponge exhibited complete bone fill at 4 wk while 70% of the animals receiving osteoactivin showed complete bone fill.Conclusion: Osteoactivin demonstrates a significant potential to support bone regeneration/formation. Studies using discriminating large animal models are necessary to explore clinical application for periodontal and craniofacial indications.